The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to sweep the globe with devastating consequences on human lives and world economy. As an RNA virus, SARS-CoV-2 has a relatively high mutation rate and is rapidly evolving. Thus, new SARS-CoV-2 variants continued to emerge, 5 of which were designated by the World Health Organization (WHO) as variants of concern (VOCs), Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and, recently, Omicron (B.1.1.529). First identified in Botswana and South Africa in November 2021, the original Omicron, BA.1, then spread to every corner of the world and quickly replaced the previously dominant Delta strain to become the most prevalent SARS-CoV-2 circulating variant across the world. BA.1 is reported to escape most therapeutic monoclonal antibodies against SARS-CoV-2. Consistently, sera from convalescent donors and vaccinated individuals contain very low to undetectable levels of neutralizing antibodies against BA.1. Therefore, new therapeutic agents are urgently needed.